Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPEHBJ)

Drug Name
OX-NLA Drug Info
Synonyms
NLA; BLX-NLA; NCX-1510; NO-donating therapeutics, Biolipox; Anti-allergy drug, NicOx/Biolipox; NO-donating allergy therapeutics, Biolipox/Nicox; NO-donating respiratory therapeutics, NicOx/Biolipox; NO-donating therapeutics, Biolipox/Nicox; Liposomal nitric oxide-donating cetirizine derivative (nasal, rhinitis), Biolipox; Nitric oxide-donating cetirizine derivative (liposomal, intranasal, rhinitis), Orexo; OX-NLA (nasal/liposomal formulation, allergic rhinitis/rhinitis); OX-NLA (nasal/liposomal formulation, allergic rhinitis/rhinitis), Meda
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
55182
ChEBI ID
CHEBI:3562
CAS Number
CAS 83881-52-1
TTD Drug ID
DMPEHBJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histamine receptor (HR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Histamine Phosphate DMV7IM6 Diagnostic imaging N.A. Approved [5]
Repirinast DM6KI0D Asthma CA23 Approved [6]
Levomequitazine DMAYC76 Seasonal allergic rhinitis CA08.01 Phase 3 [7]
ETX-9101 DMZOA2L Asthma CA23 Phase 2 [8]
LCB-2183 DMY4IWC Asthma CA23 Phase 2 [9]
ETS-6218 DMV96BY Fibromyalgia MG30.01 Phase 2 [8]
Votucalis DMW4LTI Allergic rhinitis CA08.0 Phase 2 [10]
Tesmilifene DMPB36I Breast cancer 2C60-2C65 Discontinued in Phase 2 [11]
CP-118 DMNJD9H Allergic rhinitis CA08.0 Discontinued in Phase 2 [12]
REV-598 DM314CZ Carcinoid syndrome 5B10 Terminated [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [14]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [15]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [16]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [17]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [18]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [18]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [4]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [19]
Capsaicin DMGMF6V Back pain ME84.Z Approved [20]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Polyunsaturated fatty acid 5-lipoxygenase (ALOX5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [22]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
SPI-1005 DM6XFHS Reperfusion injury ND56.Z Approved [24]
Fructose DM43AN2 Vomiting MD90 Approved [25]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [26]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [4]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [29]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Histamine H1 receptor (HRH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Desloratadine DM56YN7 Allergic rhinitis CA08.0 Approved [4]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [4]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [31]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [32]
Methotrexate DM2TEOL Anterior urethra cancer Approved [33]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [34]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [35]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Clozapine DMFC71L Schizophrenia 6A20 Approved [36]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [38]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [39]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [40]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [41]
Cepharanthine DM9Y5JB N. A. N. A. Approved [42]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [43]
Clozapine DMFC71L Schizophrenia 6A20 Approved [44]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [45]
Trifluoperazine DMKBYWI Anxiety Approved [46]
Olanzapine DMPFN6Y Bipolar depression Approved [44]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine receptor (HR) TT7CXIM NOUNIPROTAC Antagonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [3]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [4]
Histamine H1 receptor (HRH1) OT8F9FV6 HRH1_HUMAN Protein Interaction/Cellular Processes [4]
Polyunsaturated fatty acid 5-lipoxygenase (ALOX5) OT7FOIK2 LOX5_HUMAN Gene/Protein Processing [4]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020184)
2 Clinical pipeline report, company report or official report of Orexo.
3 P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
4 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
7 Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
8 Clinical pipeline report, company report or official report of e-Therapeutics.
9 LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
10 CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
11 Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
14 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
15 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
16 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
17 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
18 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
19 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
20 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
21 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
22 Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38.
23 Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34.
24 Molecular actions of ebselen--an antiinflammatory antioxidant. Gen Pharmacol. 1995 Oct;26(6):1153-69.
25 Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
26 Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta. 2005 Sep 10;1745(2):156-65.
27 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
28 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
29 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
30 Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
31 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
32 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
33 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
34 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
35 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
36 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
37 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
38 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
39 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
40 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
41 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
42 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
43 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
44 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
45 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
46 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.